Awaiting development: Guidance and quality standards

Showing 221 to 230 of 391

Guidance and quality standards awaiting development
Title	Type
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]	Technology appraisal guidance
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]	Technology appraisal guidance
Pelabresib with ruxolitinib for treating myelofibrosis [TSID12391]	Technology appraisal guidance
Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]	Technology appraisal guidance
Pelvic floor dysfunction	Quality standard
Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]	Technology appraisal guidance
Pembrolizumab for treating advanced or recurrent endometrial cancer with mismatch repair deficiency [ID6710]	Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]	Technology appraisal guidance